Dow Down0.44% Nasdaq Down0.20%

AVAX Technologies Inc. (AVXT)

-Other OTC
0.01 0.00(0.00%) Sep 22
ProfileGet Profile for:
AVAX Technologies Inc.
2000 Hamilton Street
Suite 204
Philadelphia, PA 19130
United States - Map
Phone: 215-241-9760
Fax: 215-241-9684

Index Membership:N/A
Full Time Employees:9

Business Summary 

AVAX Technologies, Inc., a development stage biopharmaceutical company, specializes in the development and commercialization of vaccine therapies and other technologies for the treatment of cancer. The company’s autologous cell vaccine immunotherapy products include M-VAX intended for the treatment of melanoma is under phase II clinical trials; and O-VAX intended for the treatment for ovarian cancer is under phase I/II trials. It also provides contract manufacturing and research services. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on AVAX Technologies Inc.

Key Executives 
Dr. John K. A. Prendergast Ph.D., 60
Exec. Chairman and Chief Exec. Officer
Mr. Howard S. Fischer , 50
Acting Chief Financial Officer
Mr. Henry E. Schea III, 61
Exec. Director of Global Manufacturing & Quality Control, Pres of Genopoietic S A and Gen. Director of Genopoietic S A
Dr. Judith A. Hemberger Ph.D., 67
Other Professional
Amounts are as of Dec 31, 2010 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders